Gide advises the European Investment Bank on €37.5 million financing for MaaT Pharma

Gide advises the European Investment Bank (EIB) on a €37.5 million venture debt financing for MaaT Pharma, a French biotechnology company listed on Euronext Paris.

The €37.5 million financing consists of four tranches, respectively of €3.5 million, €6.0 million, €8.0 million, and €20.0 million, each tranche with warrants attached.

The financing will support the advancement of MaaT Pharma late-stage hemato-oncology clinical programs including the lead-asset Xervyteg^®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants.

The EIB’s investment aligns with the InvestEU objective to encourage research, development, and innovation.

Gide’s team comprised Farah El-Bsat, partner, and Romane Chaumeil, associate, on financing matters, and Aude-Laurène Dourdain, counsel, and Yasmine Tanji, associate, on capital markets matters.